RayKnowChina Research Map
Shortlist0

Guilin Medical University

桂林医学院

GuilinUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.5%Leads about 1 in 68 of China's research papers on NPC

Led 35 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
35
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University35

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.2024JAMA oncologyRCTFree full text
  2. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]RCT
  3. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  4. Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma-Reply.2024JAMA oncology
  5. Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis.2025Radiology and oncologyFree full text
Trials on ClinicalTrials.gov6
  1. Impacted Tooth Management and Osteoradionecrosis Risk in NPCNot yet recruitingNCT07764887Study siteN/AStart 2026-08
  2. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Study sitePhase 2Start 2026-08
  3. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  4. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  5. Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal CarcinomaRecruitingNCT05717790Study siteN/AStart 2022-12
  6. Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaRecruitingNCT05527470Study sitePhase 3Start 2022-11

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.4%Leads under 1 in 100 of China's research papers on HCC

Led 66 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
66
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University66

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.09%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 9 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesEarly detection & endoscopyImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University Counted in the group total9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.1%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 3 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.3%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 3 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.2%Leads under 1 in 100 of China's research papers on Myeloma

Led 3 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.03%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025
ThemesDiagnosis, MRD & risk

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.0%Leads under 1 in 100 of China's research papers on Beta thalassaemia ▼ from 1.8%

Led 3 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
1.3%Leads about 1 in 76 of China's research papers on Hepatic echinococcosis New since 2021

Led 2 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.1%Leads under 1 in 100 of China's research papers on IgA nephropathy New since 2021

Led 1 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Guilin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Impact of crescents on the immunosuppression treatment of IgA nephropathy.2025Renal failure
Trials on ClinicalTrials.gov2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

PubMed searchClinicalTrials.gov